Illumina (NASDAQ:ILMN) CAO Scott Ericksen Sells 267 Shares of Company Stock

Illumina, Inc. (NASDAQ:ILMN) CAO Scott Ericksen sold 267 shares of the business’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $217.76, for a total transaction of $58,141.92. Following the completion of the transaction, the chief accounting officer owned 14,029 shares in the company, valued at approximately $3,054,955.04. The trade was a 1.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Performance

Shares of ILMN opened at $209.55 on Friday. The company has a current ratio of 2.63, a quick ratio of 2.05 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $31.68 billion, a P/E ratio of 36.07, a price-to-earnings-growth ratio of 2.89 and a beta of 1.46. The firm’s fifty day simple moving average is $249.32 and its two-hundred day simple moving average is $179.36. Illumina, Inc. has a 12 month low of $112.65 and a 12 month high of $309.35.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.26. The firm had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The business’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period last year, the company posted $1.34 EPS. As a group, analysts predict that Illumina, Inc. will post 5.43 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on ILMN. JPMorgan Chase & Co. dropped their price target on Illumina from $320.00 to $300.00 and set an “overweight” rating on the stock in a research note on Friday, October 30th. Guggenheim lifted their price objective on shares of Illumina from $226.00 to $305.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Deutsche Bank lowered shares of Illumina to a “hold” rating in a research note on Wednesday, August 5th. Evercore reiterated an “underperform” rating on shares of Illumina in a research report on Friday, October 30th. Finally, Stephens lowered shares of Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 target price on the stock. in a research note on Friday, October 23rd. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Illumina has a consensus rating of “Hold” and an average price target of $244.24.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Illumina during the 2nd quarter valued at $3,374,423,000. Plato Investment Management Ltd bought a new position in shares of Illumina in the second quarter valued at $948,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Illumina in the second quarter valued at $30,501,000. Edmond DE Rothschild Holding S.A. bought a new position in shares of Illumina in the second quarter valued at $129,792,000. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new position in shares of Illumina during the second quarter valued at about $6,711,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Latest Illumina News

Investors following ILMN have been watching these news items:

• Positive Sentiment: Illumina reported third-quarter revenue of $1.129 billion and net income of $220 million, raised its 2026 revenue outlook to $4.64 billion–$4.66 billion, and highlighted strength in clinical sequencing consumables. How Investors May Respond To Illumina (ILMN) Earnings Beat
• Positive Sentiment: The company expanded its molecular residual disease research portfolio with an ultrasensitive duplex sequencing workflow for circulating tumor DNA and was selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT precision-medicine study. These developments support its push into clinical oncology and sequencing applications. Illumina (ILMN) Unveils Duplex Sequencing Workflow For MRD Research
• Negative Sentiment: Director Keith Meister sold 280,091 shares over November 9–11 for approximately $61.1 million, reducing his direct holdings to 208,826 shares. The scale of the sales could raise concerns among investors, despite his continuing substantial ownership. SEC filing

About Illumina

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.